BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//Pharmaconomics//FDA Catalyst Calendar//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
BEGIN:VEVENT
UID:pharmaconomics-1017@pharmaconomics
DTSTAMP:20260707T015736Z
DTSTART;VALUE=DATE:20260701
DTEND;VALUE=DATE:20260702
SUMMARY:INBX AdCom — ozekibart (INBRX-109)
DESCRIPTION:An FDA advisory committee reviews ozekibart (INBRX-109) for colorectal cancer around Jul 1\, 2026. The panel's public vote often front-runs the agency's final verdict — and the share price.\n\nPrimary source: https://www.sec.gov/Archives/edgar/data/2007919/000200791926000028/exhibit99103312026.htm\n\nTrack it: https://pharmaconomics.com/e/1017
URL:https://pharmaconomics.com/e/1017
TRANSP:TRANSPARENT
BEGIN:VALARM
TRIGGER:-P1D
ACTION:DISPLAY
DESCRIPTION:INBX catalyst tomorrow
END:VALARM
END:VEVENT
END:VCALENDAR